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in pencil beam scanning proton 
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Giovanni fattori1*, Ye Zhang1, David Meer1, Damien charles Weber1,2,3, 
Antony John Lomax1,4 & Sairos Safai1
tumour tracking is an advanced radiotherapy technique for precise treatment of tumours subject to 
organ motion. in this work, we addressed crucial aspects of dose delivery for its realisation in pencil 
beam scanning proton therapy, exploring the momentum acceptance and global achromaticity of 
a Gantry beamline to perform continuous energy regulation with a standard upstream degrader. 
this novel approach is validated on simulation data from three geometric phantoms of increasing 
complexity and one liver cancer patient using 4D dose calculations. Results from a standard high-
to-low beamline ramping scheme were compared to alternative energy meandering schemes 
including combinations with rescanning. target coverage and dose conformity were generally well 
recovered with tumour tracking even though for particularly small targets, large variations are 
reported for the different approaches. Meandering in energy while rescanning has a positive impact 
on target homogeneity and similarly, hot spots outside the targets are mitigated with a relatively 
fast convergence rate for most tracking scenarios, halving the volume of hot spots after as little as 3 
rescans. this work investigates the yet unexplored potential of having a large momentum acceptance 
in medical beam line, and provides an alternative to take tumour tracking with particle therapy closer 
to clinical translation.
In radiotherapy, the most intuitive and efficient way to treat a tumour that moves as a result of patient breathing 
is to track its position in real time with the beam, thus keeping minimal safety margins and maximising beam-on 
time. However, this so-called tumour tracking technique is usually referred to as “challenging”1 or “unlikely to be 
implemented clinically anytime soon”2 in particle radiotherapy, partly due to the difficulty to assess the tumour 
motion reliably enough and in real  time1,3. Recent advances in image guided radiotherapy and clinical proton 
facility design have introduced on-line radiographic imaging during treatment and/or continuous monitoring 
of the patient  surface4,5, not to mention future directions of magnetic resonance guided  therapy6,7. As such, the 
main challenge now is how to adapt the treatment on-line following the patient anatomy, and how to perform this 
in a reliable and flexible way. In this study, we explore the potential of a novel approach to tumour tracking with 
an eye on the performance of the future generation of proton gantries, aiming at real-time treatment adaptation 
with the highest beam quality for clinical applications.
Tumour tracking has been implemented in photon therapy for a number of  years8–12, even if it is still a 
relatively rarely used approach. However, the dose deposited by photons decays exponentially with depth as it 
traverses through the body, and therefore real-time tracking can be effectively implemented by laterally shift-
ing the geometrical isocenter of the therapeutic beam to follow the tumour target. This functionality has been 
implemented in commercial photon machines by either moving the entire linear accelerator with a robotic arm, 
open
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(e.g. Accuray CyberKnife) or with a gimbaled MV LINAC with a multi leaf collimator (MLC) (e.g. Brainlab 
ExacTrac  VERO13). Other options available, albeit at an experimental stage, are dynamic MLC  tracking8,14 and 
real-time compensation with couch  motions15,16. Extensive use of online image guidance is made to monitor 
the target motion during the treatment, using on-board X-ray imaging to either track directly the tumour and 
related structures or, more often, fiducial markers implanted in its close proximity. Non-ionising alternatives 
are commercially available and rely on correlation models to estimate the target position from the body surface 
motion or ultrasound imaging. For a thorough review of the use of imaging for tumour tracking the reader is 
referred to Riboldi et al.3. More recently though, magnetic resonance imaging has been integrated in radiotherapy 
linear accelerators from commercial vendors, opening up new possibilities for on-line soft tissue imaging in the 
context of advanced radiotherapy workflows and motion  mitigation17. The translation of these techniques to 
particle therapy is challenging, and presents a number of very specific issues dictated by the finite range of the 
treatment beam and its dependence on the density of tissues crossed. Successful tumour tracking with particles 
therefore is strictly interrelated with accurate modelling of the whole patient anatomy in the beam  path18 and 
the rapid, on the fly, adaptation of beam settings to avoid overshooting into healthy tissues or severe distortions 
of the dose in the  target19. This latter aspect, related to on-line control of dose delivery to track intra-fractional 
organ motion is the subject of this contribution, with specific reference to proton treatments delivery with pencil 
beam scanning (PBS).
During the pencil beam scanning delivery process, spot (Bragg peak) positions are set by the therapy control 
system (TCS) individually. Although transversal beam position changes can be performed quickly, allowing for 
fast lateral tracking of the tumour, modulation of energy, in order to also track the tumour in depth, is problem-
atic due to the typically long times required for energy layer switching on most gantry systems. However, this 
is not due to the time it requires to change the position of the energy degrader or resetting the energy selection 
system, but more due to the time it takes to change the magnetic field of the dipoles magnets in order to preserve 
the position of the pencil beam at isocentre. For instance, in PBS treatments, the beamline magnets are repeatedly 
set, or technically speaking “tuned”, to follow the sequence of energies in the plan. The beam momentum varia-
tion between subsequent energy levels is about 1% and its application takes from a hundred milliseconds or so 
on fast machines like PSI Gantry 2, to more than 1 s in some facilities. Moreover, beamline magnetic ramping is 
generally performed only in one direction, e.g. from the highest to the lowest energy, to avoid complex hysteresis 
effects in the  magnets20. As a result, treatments are delivered as a sequence of discrete iso-energy layers while 
scanning transversally through the target with limited capacity for fast energy  modulation21.
The most sophisticated prototype for beam tracking experiments with particle beams was developed at the 
fixed beamline for carbon ions in the GSI Helmholtzzentrum für  Schwerionenforschung22–24. In the GSI setup, a 
wedge-based beam degrader installed downstream of the beam line nozzle was used to achieve real time energy 
modulation, while the beam was offset laterally by adapting the scanning magnet settings. Downstream degrada-
tion however, particularly for protons, can substantially broaden the pencil beam size, potentially compromising 
the lateral fall-off and dose penumbra. In addition, such an approach would require a major upgrade to existing 
proton therapy facilities.
Recent results on gantry design research inspired us however to rethink the energy modulation approach 
towards a more elegant solution that does not require a dedicated degrader downstream in the beamline and is 
therefore potentially applicable for most clinical units. For instance, aiming for reduction of costs and size for 
particle therapy facilities, PSI researchers recently proposed a compact gantry design using superconducting 
 magnets25,26. This technology is capable of a large momentum acceptance (over ± 10%) so that the beam ener-
gies required for patient treatments can be adjusted up-stream, without re-tuning the entire  beamline27,28. The 
globally achromatic design of existing gantries ensures that particles with energy within a defined momentum 
acceptance can be transported without chromatic dispersion. In other words, even particles which have non-
nominal momentum will be focused in the same point at iso-center after transport through the gantry. As such, 
ultra-fast and continuous energy regulation within the momentum acceptance can be realised with a mechanical 
degrader or energy selection system located upstream of the gantry, without the latency overhead for re-tuning 
the entire beamline. This provides a unique opportunity to realise tumour tracking with clinically acceptable 
beam shape and beam monitoring systems, while the gantry achromaticity ensures accuracy in beam position-
ing in the patient.
Planning for tumour tracking starts with the acquisition of time resolved 4D  imaging29 such as 4DCT or 
4DMRI. A treatment plan is then typically optimised on one selected reference image, and the remaining phases 
used to derive lateral position offsets and energy changes required to track each Bragg peak (also referred to 
as a ‘spot’), by taking into account the tumour position and any deforming anatomies through which the beam 
needs to pass (Fig. 1). The momentum acceptance of clinically available beamlines is however reduced compared 
to aforementioned studies on superconductivity and therefore tracking corrections cannot be selected arbitrar-
ily on-the-fly without frequent beamline tune changes. Our strategy for making use of even a relatively small 
acceptance is to drop the canonical scanning path in favour of a less regularised meandering scheme, which 
follows the deforming anatomy of the patient. By making reasonable assumptions about the breathing pattern 
reproducibility, it is possible to generate a different type of spot list that is not structured in a sequence of iso-
energy layers scanned across with spots on a regular grid, but that instead takes into account the progressive 
anatomical changes. In a respiratory correlated irradiation, the patient breathing and the beamline ramping run 
in synchrony and the spots that, including tracking offsets, match the instantaneous combination of breathing 
phase and available energy are progressively selected for delivery. Leveraging on the flexibility of PBS units in 
setting the transversal beam position, the monotonic progression of energies is the driving criteria of such a 
meandering scheme that requires fewer beamline tunes, but instead, a continuous energy regulation within each 
tune’s respective momentum acceptance. In addition, energy meandering was introduced to eliminate the dead 
time required for beam line ramping, for an optimal treatment duty cycle. In the absence of specific 4D planning 
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optimisation, inhomogeneities may be expected in the entrance channel, upstream to the target and in the target 
 itself30. This problem is further addressed by combining tumour tracking with rescanning in order to mitigate 
the dose corruption through multiple deliveries of the plan under different interplay conditions.
The feasibility of ultra-fast energy changes within the beam line momentum acceptance, exploiting the high 
level of achromaticity of next generation treatment gantries, opens new and unexplored opportunities for beam 
tracking applications and on-the-fly treatment adaptation. In this paper therefore, we investigate the potential of 
this approach through simulations using first simple geometric cases in order to fully understand the advantages 
and limitations of the approach in easy to interpret geometries, and then in an example clinical case.
Results
Tumour tracking results are reported for single field, single fraction treatment of four test cases (Table 1) using 
4D dose  calculation18.
Three geometric moving phantoms S1, S2 and S3 simulate increasingly smaller spherical targets moving 
behind a dense cylindrical rod. The structures’ densities have been set to mimic the treatment of soft tissue 
tumours (100 HU) moving in a water bath (0 HU), behind a bony element of the rib cage (1,000 HU). Simplified 
rigid motion of 20 mm range, transversal with respect to the beam, has been considered for these cases and 
sampled in 10 synthetic CT phases. P1 is a liver cancer patient published in Zhang et al.31 (Patient III, Motion 
B) with a medium size tumour in the anterior superior segment (VIII) of the right lobe. The 4D CT images used 
in this study were obtained by warping one phase of the patient 4DCT with the deformation fields derived from 
4D MR imaging to generate 20 motion phases with temporal resolution of 2.7  Hz32. Patient breathing has been 
modelled using a multiresolution B-spline deformable image registration algorithm implemented in the Plasti-
match  software33. With this approach, clinically plausible breathing irregularities can also be modelled to more 
thoroughly test proposed 3D tracking approach. In these data sets, the tumour moves 2 cm primarily in the 
superior-inferior direction during breathing, as well as deforming up to about 10% of its volume. In all cases, a 
planning target volume (PTV) has been obtained using a 2 mm isotropic expansion of gross tumour volume, 
and planned with a prescribed dose of 1 GyRBE. The PTV margin has been kept intentionally small, much lower 
than clinically used expansions, such as to make the plans sensitive even to the smallest dose disturbances that 
would potentially be hidden by the use of larger safety margins instead. With this choice, adequate treatment 
conformity (V95 > 95%) was ensured in static conditions for all cases but S3, in which the small size of CTV and 
synthetic bone structure compared to the beam size at target depth limit the dose conformity. Nevertheless, to 
ensure consistency in our plan comparisons, S3 has also been planned with 2 mm margins. All plans consisted 
Figure 1.  Sketch of energy offsets for beam tracking in a simplified treatment plan consisting of 8 spots 
distributed over three energy levels (E1, E2, E3). Reference spot energy is altered as a function of a high-density 
structure (e.g. rib cage bones) crossing the field during patient breathing. Individual spot energy is increased as 
function of material density in his path. Three motion phases are displayed (Reference, Phase I, Phase II).
Table 1.  Dataset characteristics including PTV/CTV size, motion amplitude and period, volume deformation 
observed over 4D imaging. *Actual values from the contours drawn on sub-sampled image volumes used for 
treatment planning.
Description PTV size  [cm3]* CTV size  [cm3]*
Motion amplitude, 
PTV center of mass 
[mm] Motion period [s]
PTV volume 
deformation [%]
S1 Sphere 8 cm diameter 260.672 227.86 SI: 20 3 0
S2 Sphere 4 cm diameter 31.636 23.908 SI: 20 3 0
S3 Sphere 2 cm diameter 3.724 2.012 SI: 20 3 0
P1 Liver cancer patient 365.353 314.59 LL: 2.18; AP: 2.18; SI: 18.63 7.22 + 2.95/− 6.57
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of a single field resulting from Single Field Uniform Dose (SFUD) optimisation. Gantry momentum acceptance 
considered was p
/
p = ±0.6% , a realistic value for PSI Gantry 2 and commercial treatment  units
34.
The International Commission on Radiation Units and Measurements (ICRU) recommendations were fol-
lowed to evaluate dose quality for conformity CI := TVD98%PTV  , defined as ratio between the volume of the 98% 
isodose and the PTV, and hot-spots (HS) as the volume of tissue outside the 2 mm expansion of PTV that receives 
a dose greater than the target prescription. In addition, CTV dose coverage and homogeneity have been evalu-
ated as  V95% (the volume of the target receiving at least 95% of the prescription dose) and the homogeneity index 
defined as HI := D5%−D95%.
Dose quality indices for single tracking deliveries under the condition of motion (Fig. 2) were compared with 
reference values in stationary condition and free-breathing treatments without mitigation (Table 2). Four tracking 
scenarios have been simulated and compared: (1) with (WEM) and (2) without (WoEM) energy meandering, 
and (3) starting at high or (4) low energies. Treatment conformity is recovered exceptionally by means of tumour 
tracking for all cases but S3, where despite a significant improvement on the median value (− 85% of unmitigated 
case) a large range of variation is reported among the different tracking techniques. Inhomogeneity is within 
20% for S1 and S2, with larger median values for S3 and P1 and substantial variations among scenarios for the 
former. Single tracking is also shown to restore V95 for all geometric phantoms, whereas the liver cancer case 
scores a sub-optimal 76.9%. Similarly, the volume of hot spots is marginal in S1, S2 and S3 but are comparable 
to the unmitigated case for the patient data simulations.
The delivery times for each simulated scenario have been estimated using the timing model of PSI Gantry2 
from Klimpki et al.35 (Table 3). The model is built on machine log files from patient treatments and parametrises 
the energy dependency of beam current transmission between 70 and 230 MeV. Relevant for this study are the 
mean time required to initialise all beam line elements (full ramping) and mean dead time for small energy 
changes of clinical treatments, which are respectively set at 9.3 s and 106 ms. Additionally, the model has been 
extended to simulate energy meandering, in which the beamline is only transitorily set at the corresponding 
energy bound, obviating the need of a full  ramping20. In this case, the dead time on our machine is 1 s. Based 
on this, the duration of tracking treatments using energy meandering was only marginally higher than the 
conventional plan without tracking. Without meandering in energy, several full beam line rampings during the 
delivery would substantially increase the treatment time, which is at least double the duration of conventional 
plans. The selection of starting energy, whether high at 230 MeV or low at 70 MeV was shown to have only a 
minor role in most cases.
The small sphere target (S3) and liver patient (P1) are challenging cases to treat with proton beams. The 2 cm 
diameter sphere S3 is rather small compared to the proton beam size at the target depth, impairing the plan 
quality even in stationary conditions. Moreover, during the breathing cycle, it moves completely out of the shade 
of the dense cylindrical rib model, requiring substantial energy adaptation. P1 has a tumour in the upper lobe 
of the liver whose apex is neighboured proximally and distally by air in the right lung, a steep density gradient 
to account for in proton treatments. Implanted metallic seeds and the volume deformation impact further on 
the complexity of P1 test set. For those cases therefore, we have analysed in more detail the effect of each track-
ing technique and the potential of rescanning to reduce target inhomogeneity and hot spot in proximal tissues 
upstream of the target (Fig. 3).
Meandering in energy when rescanning has a positive impact on target homogeneity, resulting in more stable 
HI indices approaching the values of the stationary condition. This effect is pronounced on the spherical test case 
S3, whereas in the liver patient P1 its impact is hidden by the fact that the simple Bragg peak tracking technique 
without specific 4D plan optimisation is reaching its limits of homogeneity. Differences between the starting 
energy directions can be observed for S3, even though this is not significant considering the full cohort. Hot spot 
analysis is more appropriate for the patient data, as the homogeneous media in which the sphere target is moving 
is more forgiving for hot spots. Similarly, hot spots outside the targets in P1 are mitigated by rescanning with a 
relatively fast convergence rate for most of tracking modalities, halving the HS volume after as little as 3 rescans. 
In this regard, the tracking scenario simulated is not a significant parameter, except for the case of rescanning 
starting from low energies and without meandering, that diverges with the increase of the number of rescans.
Discussion
Elaborating on tumour tracking is an opportunity to investigate the yet unexplored potential of exploiting large 
momentum acceptance of proton gantries and beam lines to achieve ultra-fast energy regulation and beam 
offsets. In fact, we build on the latest available results regarding the delivery of tumour tracking treatments in 
particle therapy to address the energy regulation from a different perspective, thus providing a solution that 
does not require significant changes in the beamline and capable of clinical level beam quality. As demonstrated 
in this proof-of-concept study, the method is indeed applicable to clinical cases, with dosimetric results that 
are well aligned with the reference literature on tumour tracking. Unlike all currently available implementa-
tions however, potentially our concept does not require any additional hardware and this may be the key for its 
translation into the clinic of facilities that feature an energy degrader upstream in the beamline, as most of the 
running treatment units are.
fast energy regulation. Magnetic beam deflection on a static wedge degrader as described by Chaudhri 
et al.36 is possibly the fastest method to control the energy, promising beam energy selection on the same time 
scale as lateral scanning. This is however not the standard of clinical units that, most often, rely on motor driven 
double-wedge37 or multi-plates38 mechanical degraders. Albeit having lower performance, such mechanical 
devices have already been used to regulate the energy on a spot-by-spot basis in experimental tumour tracking 
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 studies24. Adopting time prediction to compensate for communication delays, around 20 ms actuation time for 
around 5 mm water equivalent range shift is achieved in those cases. The wedge travel to regulate the energy 
within the momentum acceptance is however expected to be a fraction of that value, making it theoretically 
possible to reach fast performances. Moreover, our pencil beam scanning implementation is a discrete (step-
Figure 2.  Dose distributions on sagittal plane cut at isocenter. Reference plan delivered on stationary anatomy 
is compared with 4D dose calculation without motion mitigation and for three rescan factors. PTV and CTV 
contours are shown respectively in blue and red. Axes are millimetres, dose expressed as percent of CTV 
prescription.
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and-shoot) method, i.e. the beam is turned off in between of the spots, with a dead time of 2.83 ms (mean)35 that 
leaves some margin for controlling the energy degrader.
Beam losses. A realistic model of the dose delivery dynamic is essential in the process of spot sorting, to 
generate a similar delivery sequence that is synchronous with the patient breathing. Critical in this regard is the 
accuracy in the estimate of the current loss for off-momentum particles. Particles with non-nominal momen-
tum within the acceptance, ± 0.6% by design in our case study, although transported through the gantry, may be 
chromatically dispersed in the beamline, leading to transmission losses. This should not however be problematic 
in current cyclotron-based facilities, reporting extremely low latency in current control (nominally 100 micro-
seconds at  PSI34) and therefore being compatible with tracking applications and on-the-fly current corrections. 
Besides, as the beam line transmission is a function of the particles momentum within the acceptance, the cur-
rent corrections can be pre-computed at the time of treatment planning and made available for delivery. Accord-
ingly, in this simulation study the beam current at isocentre for all energies within the beamline acceptance is 
therefore assumed to be in line with the clinical standard of Gantry 2 operation at PSI. Notwithstanding, this 
modality requires high standards in the regulation of the accelerator current such as to restore beam intensity at 
iso-center as planned.
Table 2.  Median (range) of dose quality indices of four different single tracking modalities. Reference values 
in stationary and unmitigated free-breathing conditions are reported for comparison.
CI HI [%] V95 [%] HS  [cm3]
S1 4.1 1.5 (0.3) 1 65.3 10.4 (0.7) 3.1 49.9 94.9 (3.1) 99.3 26.06 1.3 (3.1) 0.18
S2 9.3 2.3 (0.2) 1.3 73.4 18.4 (4.8) 5.4 23.6 92.4 (8.4) 97.4 6.72 0.1 (0.3) 0.12
S3 43 6.4 (10.4) 2.1 42.7 33.1 (26.3) 12.9 0 91.5 (15.4) 86.8 1.95 0.3 (0.6) 0.06
P1 3.8 1.5 (0.1) 1.1 65.3 24.9 (5.9) 5.5 48 76.9 (5.7) 98.6 20.03 20.6 (11.1) 1.67
No mitigation Tracking Stationary No mitigation Tracking Stationary No mitigation Tracking Stationary No mitigation Tracking Stationary
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Figure 3.  CTV homogeneity (HI) and hot spots volume (HS) outside the PTV as a function of the rescan 
factor, for each tracking modality; with (WEM) or without (WoEM) energy meandering and starting with 
Low or High energy. Results from stationary irradiation and 4D dose calculation without tracking are shown 
respectively as solid and dashed black lines.
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tumour tracking with a limited momentum acceptance. Momentum acceptance is a well-defined 
property of the beamline, which depends on the design and configuration of elements, and whose width sets the 
boundaries of beam energy regulation. This may be less of an issue for next generation gantry designs but it can 
be limiting in existing facilities that have just a few percent acceptance. As has been shown in this study, however, 
even a limited band of ± 0.6% may have potential for beam tracking. For a 230 MeV proton beam, about 2 mm 
water equivalent range corrections can be set on the fly, without changing the beamline energy tune. This value 
scales with decreasing energies, and at the lower-end of clinical tunes (70 MeV) becomes so little to be meaning-
less. Therefore, to enable larger beam energy corrections, high energies should be preferred, adding an offset 
in the treatment plans if required. For this, a thick slab of compensating material close to the patient may be 
required to degrade from these higher energies to clinically relevant ranges (see e.g.39,40). Unlike the downstream 
wedge system used for experimental tracking measurements, such degrading material would be a fixed element 
that can be in close contact with the patient skin, thus minimising the beam  broadening39,41.
energy meandering. The possibility to perform energy meandering is not only useful to improve the duty 
cycle of the treatment (see Table 3) but also provides additional flexibility in the spot sequence optimisation. 
Simply put, using the standard high-to-low energy progression would probably have a bias towards the use of 
pencil beams with high ranges and therefore favours the treatment of anatomical conditions where high density 
structures are in front of the target. The energy sequencing however can be flipped to low-to-high energy sorting 
to minimise the chances of treating through bones and complex heterogeneities. Whether to start with high or 
low energy, or introduce energy meandering, is however to be evaluated in accordance to the respiratory phase 
used to create the nominal plan. When treatment delivery starts from high energy in a breathing phase far apart 
of the planning image, high weight spots in the distal part of the target are delivered with systematically larger 
tracking offsets, thus increasing the probability of dose corruption and inverse interplay that are unlikely to be 
compensated throughout the treatment. An ideal case to observe this behaviour is S3, that indeed reports large 
variations in target dose conformity and homogeneity among the different tracking sequences. This effect is 
however mitigated by the application of rescanning, introducing random changes in the delivery sequences. 
Even very few rescans are enough to observe a significant improvement in the conformity and reduction of dose 
hot spots outside the target as reported in Fig. 3, for the small spherical target and clinical liver cancer patient.
tumour tracking and rescanning. As has been presented, our concept, which does not require re-optimi-
sation of the original treatment plan, is prone to the inverse-interplay effect in tissues upstream of the  target18,23. 
Target dose degradation can also be introduced by the pencil beam shape corruption due to the differences in 
tissue heterogeneities in the tracked geometry compared to the planning  image30. The simplest approach to 
tackle such criticalities is rescanning—that averages out inhomogeneity over multiple rescans of the treatment 
field. Combining rescanning with our energy sequencing is however complicated. As we do not rely on canonical 
pencil beam meandering in iso-energy layers, the concept of layered  rescanning42 does not fit with this imple-
mentation of tumour tracking. Volumetric  rescanning43 instead has been integrated in the energy sequencing 
routine, by taking into account the time dependency of the delivery and avoiding repeated irradiation of spots in 
breathing phases that are close together. In our implementation, unlike conventional methods, the sequence in 
which the spots are delivered changes in each rescan, depending on the interplay between the respiratory phases 
and the progression of the beamline tunes. This, in fact, may bring additional stochasticity in the rescanning, 
with potential benefit on the overall effectiveness. It should be noted however, in our simulations, the minimum 
deliverable spot weight of our machine has not been considered explicitly. However, as shown in Fig. 3, for a 
clinically relevant case (P1) dose hot spots and homogeneity reported a rather quick convergence rate, reach-
ing relatively stable values after just 2–3 rescans. In such a rescanning regime, minimum spot weight is not of 
concern, in particular considering that the beam current regulation in Gantry 2 is controlled on a spot-by-spot 
 basis44.
Alternative approaches to compensate for inverse interplay can be found in the literature, addressing the 
problem at either the time of treatment planning like 4D  optimisation45 or delivery, such as the case of real-time 
dose compensation from Lüchtenborg et al.19. These methods, however, are not the definitive solution to the 
problem of controlling energy in real time during dose delivery, but instead can take advantage of the method 
proposed here to take a step towards the implementation and testing in a clinical treatment unit, without the 
need for experimental hardware and instrumentation.
Table 3.  Delivery time of tracking plans with (WEM) and without (WoEM) energy meandering considering 
the starting energy dependency (High or Low). Reference values for conventional deliveries without tracking 
are reported as ‘Standard’.
Delivery time [s]
Standard Tracking WEM Tracking WoEM
S1 41.5 49.7 53.3 74.2 87.2
S2 9.9 16.2 16.2 31.1 30.8
S3 3.3 4.9 5.6 13.2 25.8
P1 47.3 58.3 57.9 98.7 91.1
Starting Energy High High Low High Low
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Dealing with breathing irregularities and motion-induced density changes. In the most effi-
cient possible realisation of tumour tracking, the patient, with his/her individual breathing pattern drives the 
treatment. We have instead described a breathing synchronised irradiation modality that is feasible taking into 
account technical and implementation constraints, but which however requires a certain prior knowledge of the 
breathing pattern. Treating irregular breathers would require however more freedom in energy regulation, not 
tied up to a strict ramping direction. Interestingly, this holds true within the energy bands, where both positive 
and negative range corrections are possible without changing the magnets settings. Therefore, should beamlines 
with large acceptances become reality, an option not considered in the present study, would provide improved 
flexibility for tumour tracking in presence of range variations. Moreover, the use of a spot list sorted by tracked 
energies as described would be the correct starting point, as range variations would occur more gradually com-
pared to a normal beam meandering scheme that follows a sequence of energy layers.
Graeff46 has reviewed several approaches to 4D optimization that are of particular relevance for tumour 
tracking applications. By using the entire 4D image dataset during planning, these methods largely solve the 
drawbacks of simple 3D planning, which does not take into account the distortions in dose depositions along 
the pencil beam track and the interference pattern in the entrance channel (reverse interplay) resulting from 
tumour tracking. For the most part, these treatment techniques require the synchronization of the delivery 
with the respiratory movement and can therefore benefit from the method presented here, which is based on 
the same assumption but also can, in principle, take into account irregularities in breathing amplitude and base 
line shifts. The robustness aspects of 4D planning has recently been addressed by Wolf et al.47 using a dataset of 
lung cancer patients treated with rescanning, using worst-case optimisation to substantially improve the plan 
robustness against various treatment uncertainties, including range changes and deformable motions. However, 
at least for cases where the motion is too large to be mitigated with rescanning only or where the price to pay on 
the organs at risk to achieve target coverage with robust optimisation only would exceeds the clinical benefit, its 
combination with beam tracking should not be excluded.
Finally, the clinical realisation of tumour tracking with particles however cannot leave aside equally accurate 
online image guidance. The direct translation of motion monitoring techniques from conventional X-ray therapy 
can provide geometrical information, but the resulting density changes in the treatment field aren’t directly 
modelled by the real time knowledge of the target position, a crucial aspect for proton therapy applications. 
Ideally, proton radiography images can provide a direct measurement of the relative stopping power changes 
induced by the breathing motion, and as recently shown by Palaniappan et al.48, a limited number of projection 
are enough to warp (actualise) the planning CT image. Its technical realisation for time resolved 4D imaging is 
however not reality yet and therefore alternative approaches have to be considered. Near(er) future applications 
therefore entails the use of more conventional in room volumetric imaging technologies such as 4D cone beam 
 CT49, magnetic  resonance17 or  ultrasound50,51, as surrogates to update the treatment plan based on the patient’s 
breathing and synchronise the delivery.
Methods
Our approach starts off with conventional 3D treatment plan optimisation on a reference stationary image taken 
from the available set of 4D CT phases or a meaningful combination of  these52. All pencil beams are then tracked 
over the 4D images deriving the required lateral and energy corrections that are required to restore the Bragg 
peaks positions in the deforming patient anatomy. This results in a pool of treatment plans, one per breathing 
phase, which is further processed by sorting each by energy, to generate a spot list for tumour tracking that takes 
into account the dynamic of the breathing and dose delivery.
Spot tracking over 4D images. The reference treatment plan contains the list of pencil beams whose 
position is given by the scan spot transversal coordinates (u, t) as projected onto the machine isocentric plane 
in gantry coordinates and the respective nominal beam energy (E) . It is however convenient for our purposes to 
give a geometrical representation of spots with respect to isocenter by defining a third dimension (s) , in depth, 
along the beam axis. With reference to Fig. 4, (uts)− coordinates define a regular grid, centred at isocenter, 
which can be conveniently mapped onto the DICOM imaging system reference to derive the tissue density of 
each node from CT intensity values. Consequently, the equivalent range in water at 80% of Bragg peak fall-off 
(BP) is calculated for each pencil beam by accumulating the tissue stopping power along the s-nodes on the beam 
track. Due to grid discretisation, linear interpolation among the two n1,n2 adjacent nodes either side of the nomi-
nal water equivalent range of the spot is applied to obtain the actual BPUTS position for each given beam energy.
The deformation of the (uts)− coordinates grid at each breathing phase is computed with deformable image 
registration between the planning image and all other phases of the 4D dataset. The resulting deformation fields 
are used to warp the n1n2  segment (the line joining  n1 and  n2) to which the spot belongs, so as to obtain the 
positions of its endpoints ( n′1, n2′ ), in each breathing phase. In a simplified approach, the Bragg peaks of the spots 
in the nominal plan are expressed as relative distances from n1  along  n1n2 and the updated BP′UTS are located 
along 
−
n′1n
′
2 at a proportional distance from n
′
1 , preserving its relative position along the new segment. Finally, the 
actual water equivalent range, and so the energy, of each warped spot position is calculated by trilinear interpola-
tion of the eight vertices defining the bounding box of BP′UTS (blue nodes in Fig. 4).
As a result of this process, the reference plan is replicated for each available breathing phase, making sure that 
the Bragg peak positions are tracked to the corresponding anatomical location as in the reference treatment plan.
Spot sequence optimisation. Spot sorting is based around three concepts referred to as energy bands, 
energy sequencing and beam pauses.
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15325  | https://doi.org/10.1038/s41598-020-71821-1
www.nature.com/scientificreports/
Energy bands. The design and configuration of the magnets along the beamline determine its momentum 
acceptance. As such, the term “energy band” refers to the range of energies around the nominal momentum of 
particles that can be transported through the beamline for each given beamline tune setting. In most existing 
proton gantries, this gap is small and limited to just a few percent of the nominal energy. However, it is possible 
to generate high-resolution beamline tunes so that the corresponding energy bands are adjacent and cover the 
full energy range required in a treatment plan.
Energy sequencing. Due to technical constraints, magnetic ramping of the beamline is typically performed only 
in one direction and consequently, random jumps between energy bands should be avoided. Leveraging the high 
flexibility of PBS units in controlling the lateral beam position, a new scan path for tumour tracking can be gen-
erated, prioritising energy sorting to avoid meandering changes. Following the standard high-to-low ramping 
scheme, the spot list from the nominal treatment plan, together with its replicas for each respiratory phase are 
globally sorted by decreasing energy in order to identify the one that, including tracking offsets, has the highest 
energy. Such spots, and their corresponding breathing phase, are the starting point to create a plausible sequence 
to be delivered synchronised to the patient motion. Starting from this initial condition, spots in descending 
order of energy are progressively selected for delivery on the respiratory phases considering the time needed for 
dose delivery, beamline tune changes and the patient’s breathing period. Once a spot is selected for delivery, it 
is removed from the pool of all phases, thus preserving the number of spots and total dose of the nominal treat-
ment plan. In such a way, the correct descending progression of energy tunes is observed during treatment, while 
tracking the tumour motion. The workflow of this procedure is shown in Fig. 5.
Beam pauses. In this implementation of tumour tracking, monitoring breathing motion is essential to trigger 
the start of treatment and keep the synchrony between the energy sequence and respiratory phases. However, 
due to the interplay between the energy sequencing and patient motion, certain phases may be empty or, more 
likely, the number of spots in sorted energy order may not be enough to fill the duration of each breathing phase. 
In such cases, the delivery has to be paused to keep the synchrony and preserve the treatment structure.
A schematic of spot sorting is shown in Fig. 6 for the simplified tracking plan of Fig. 1 in the introduction 
section. In this example, the spot with the highest energy, including tracking offset, belongs to the first breath-
ing phase (Phase I, yellow spot). Three spots can be delivered before switching to the second energy band in 
the breathing Phase II. When coming to the next breathing phase (Reference), no spots are left to be delivered 
in the current or immediately following energy band and therefore beam is paused until the end of Reference 
phase, thus ensuring continuity in the progression of energies. Afterwards the treatment proceeds by moving to 
the following energy band and again a full pause on Phase II is required before completing the treatment with 
the last spot.
Figure 4.  Tracking the Bragg peak position over 4D images. Representation in treatment field 
(uts)− coordinates.
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Advanced energy meandering and rescanning. Since it is likely that the complete treatment plan can-
not be delivered in a single beamline ramp down, the dead time in this type of tumour tracking treatments could 
be substantial due to the need to ramp through the energies multiple times. The impact of that on the treatment 
efficiency is shown in Fig. 7 (top-left panel—orange data) for the liver case P1 considering 9.3 s ramping time (a 
figure representative of PSI Gantry 2). We introduce therefore energy  meandering20 such that when the lowest 
tune is reached, the energy progression is inverted and remaining spots delivered in ascending energy order. 
This process, repeatedly applied until treatment completion, ensures minimal dead time, bringing tracking treat-
ments virtually close to 100% duty cycle (Fig. 7, top—left panel—blue data).
Volumetric rescanning can also be applied in this context, with only a slight modification of the energy 
sequencing routine. Following conventional  methods42, the nominal dose of each pencil beam is divided by the 
rescan factor to obtain actual weights per-scan. After the first scan through the whole treatment field, the first 
spot of the next rescan is selected from those available in the current energy band of the beamline, and breathing 
phase that the patient is in. It is therefore most probable that pencil beams are rescanned to different breathing 
phases with specific tracking offsets, thus preserving the stochasticity of the method that makes rescanning effec-
tive. No methodological constraints limit its combination with energy meandering, making possible efficient 
tumour tracking with rescanning Fig. 7 (lower panel).
Figure 5.  Flow chart of the energy sequencing procedure for tumour tracking spot list generation.
Phase I Phase II Reference Phase I Phase II Reference
PAUSEPAUSE
En
er
gy
 b
an
ds
time
Energy tune
Energy tune
Energy tune
Energy tune
Energy tune
Figure 6.  Motion correlated delivery of a simple tracking plan from Fig. 1 making use of the energy bands 
concept to implement tumour tracking energy offsets.
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